Cost-Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study)
Por:
Pérez A, Francesco D'Amico, Feliu A, McCracken LM, Peñarrubia-María MT, Andrés L, Angarita-Osorio N, Martin Knapp, García-Campayo J and Luciano JV
Publicada:
1 jul 2019
Ahead of Print:
20 jul 2019
Categoría:
Medicine (miscellaneous)
Resumen:
Fibromyalgia (FM) is a prevalent, chronic, disabling, pain syndrome that implies high healthcare costs. Economic evaluations of potentially effective treatments for FM are needed. The aim of this study was to analyze the cost-utility of Mindfulness-Based Stress Reduction (MBSR) as an add-on to treatment-as-usual (TAU) for patients with FM compared to an adjuvant multicomponent intervention (FibroQoL) and to TAU. We performed an economic evaluation alongside a 12 month, randomized, controlled trial; data from 204 (68 per study arm) of the 225 patients (90.1%) were included in the cost-utility analyses, which were conducted both under the government and the public healthcare system perspectives. The main outcome measures were the EuroQol (EQ-5D-5L) for assessing Quality-Adjusted Life Years (QALYs) and improvements in health-related quality of life, and the Client Service Receipt Inventory (CSRI) for estimating direct and indirect costs. Incremental cost-effectiveness ratios (ICERs) were also calculated. Two sensitivity analyses (intention-to-treat, ITT, and per protocol, PPA) were conducted. The results indicated that MBSR achieved a significant reduction in costs compared to the other study arms (p < 0.05 in the completers sample), especially in terms of indirect costs and primary healthcare services. It also produced a significant incremental effect compared to TAU in the ITT sample (Delta QALYs = 0.053, p < 0.05, where QALYs represents quality-adjusted life years). Overall, our findings support the efficiency of MBSR over FibroQoL and TAU specifically within a Spanish public healthcare context.
Filiaciones:
Pérez A:
Group of Psychological Research in Fibromyalgia Chronic Pain (AGORA), Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
Teaching, Research Innovation Unit, Parc Sanitari Sant Joan de Déu, 08830 Sant Boi de Llobregat, Spain
Primary Care Prevention and Health Promotion Research Network, RedIAPP, 28029 Madrid, Spain
Department of Clinical Psychology and Psychobiology (Section Personality, Assessment and Psychological Treatments), University of Barcelona, 08193 Barcelona, Spain
Francesco D'Amico:
The London School of Economics and Political Science (LSE), London WC2A 2AE, UK
Feliu A:
Group of Psychological Research in Fibromyalgia Chronic Pain (AGORA), Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain.
Teaching, Research Innovation Unit, Parc Sanitari Sant Joan de Déu, 08830 Sant Boi de Llobregat, Spain.
Primary Care Prevention and Health Promotion Research Network, RedIAPP, 28029 Madrid, Spain.
McCracken LM:
Department of Psychology, Uppsala University, SE-751 05 Uppsala, Sweden
Peñarrubia-María MT:
Primary Health Centre Bartomeu Fabrés Anglada, SAP Delta Llobregat, Unitat Docent Costa de Ponent, Institut Català de la Salut, 08850 Gavà, Spain
Centre for Biomedical Research in Epidemiology and Public Health, CIBERESP, 28029 Madrid, Spain
Fundació IDIAP Jordi Gol I Gurina, 08007 Barcelona, Spain
Andrés L:
Group of Psychological Research in Fibromyalgia Chronic Pain (AGORA), Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
Teaching, Research Innovation Unit, Parc Sanitari Sant Joan de Déu, 08830 Sant Boi de Llobregat, Spain
Primary Care Prevention and Health Promotion Research Network, RedIAPP, 28029 Madrid, Spain
Angarita-Osorio N:
Group of Psychological Research in Fibromyalgia Chronic Pain (AGORA), Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
Teaching, Research Innovation Unit, Parc Sanitari Sant Joan de Déu, 08830 Sant Boi de Llobregat, Spain
Martin Knapp:
The London School of Economics and Political Science (LSE), London WC2A 2AE, UK
Centre for Biomedical Research in Epidemiology and Public Health, CIBERESP, 28029 Madrid, Spain
García-Campayo J:
Primary Care Prevention and Health Promotion Research Network, RedIAPP, 28029 Madrid, Spain
Department of Psychiatry, Miguel Servet Hospital, Aragon Institute of Health Sciences (I+CS), 50009 Zaragoza, Spain
gold, Green Published
|